Harrison, Michael R. http://orcid.org/0000-0003-3776-8892
Davis, Paul G.
Khouri, Michel G.
Bartlett, David B. http://orcid.org/0000-0001-7838-898X
Gupta, Rajan T.
Armstrong, Andrew J. http://orcid.org/0000-0001-7012-1754
McNamara, Megan A.
Zhang, Tian http://orcid.org/0000-0001-8914-3531
Anand, Monika
Onyenwoke, Kelly
Edwardson, Sara
Craig, Danielle
Michalski, Meghan
Wu, Yuan http://orcid.org/0000-0001-8925-555X
Oyekunle, Taofik
Coyne, Brian
Coburn, Aubrie
Jones, Lee W.
George, Daniel J. http://orcid.org/0000-0002-0836-8542
Funding for this research was provided by:
Pfizer
Astellas Pharma US
Article History
Received: 29 October 2021
Revised: 5 February 2022
Accepted: 16 February 2022
First Online: 10 March 2022
Competing interests
: MRH has received funding from the following: Astellas (PI), AstraZeneca (PI, Consultant), Bayer (PI), Bristol Myers Squibb (PI, Consultant), Clovis Oncology (PI), Exelixis (Speaker, PI, Advisory Board, Consultant), Fujifilm (Consultant), Genentech (PI), Merck (PI), Pfizer (PI, Advisory Board, Consultant), Seattle Genetics (PI, Advisory Board, Consultant). AJA has received funding from the following: - Dendreon Valeant Corp (PI, Consultant, Other), Astellas Pharma (PI, Consultant, Other), Clovis (Advisory Board, Consultant), AstraZeneca (PI, Advisory Board, Consultant), Janssen (PI, Consultant, Other), Bayer (PI, Consultant, Other), Merck (PI, Advisory Board, Consultant), BMS (PI, Advisory Board, Consultant), Amgen (PI), Pfizer (PI, Advisory Board, Consultant), Genentech/Roche (PI), Constellation (PI), Forma (PI, Consultant). TZ has received funding from the following: Novartis (PI), Merrimack (PI), AbbVie/Stemcentrx (PI), Merck (PI), Regeneron (PI), Mirati Therapeutics (PI), Exelixis (Advisory Board), Janssen (PI, Advisory Board), Pfizer (PI, Advisory Board, Consultant), QED Therapeutics (Advisory Board), BMS (Advisory Board), Dendreon (Advisory Board), OmniSeq (PI), Personal Genome Diagnostics (PI), Aravive (Consultant), Seattle Genetics (Advisory Board), Eisai (Advisory Board), MJH Associates (Consultant), Pacific Genuity (Consultant). DJG has received funding from the following: American Association for Cancer Research (Other), Astellas (PI, Advisory Board, Consultant), AstraZeneca (PI, Advisory Board, Consultant), Axess Oncology (Other), Bayer Pharmaceuticals (Speaker, Consultant, Other), BMS (Consultant, Research, Other - Steering Committee), Calithera (Research), Capio Biosciences (Advisory Board), Constellation Pharmaceuticals (Consultant), EMD Serono (Other - Honorarium), Exelixis, Inc (Research, Consultant, Speaker, Other - Honorarium, Travel Accommodations), Flatiron (Consultant), IDEO Oncology (Consultant), Ipsen (Other - Honorarium), Janssen Pharmaceuticals (Research, Consultant, Other - Independent Data Monitoring Committee), Merck Sharp & Dohme (Consultant), Michael J Hennessey Associates (Consultant, Other - Honorarium), Millennium Medical Publishing (Other - Co-Editor-in-Chief), Modra Pharmaceuticals B.V. (Advisory Board), Myovant Sciences, Inc (Consultant), NCI Genitourinary Steering Committee (Other - Member), Nektar Therapeutics (Other - Steering Committee), Novartis (Research), Physician Education Resource, LLC (Consultant), Pfizer (Research, Consultant, Other - Steering Committee, Honorarium), Propella TX (Consultant), RevHealth, LLC (Consultant), Sanofi (Research, Consultant, Speaker, Other - Honorarium, Travel Accommodations), UroGPO (Other - Honorarium), UroToday (Other - Honorarium, Travel Accommodations), Xcures (Consultant). PGD, MGK, DBB, RTG, MAM, MA, KO, SE, DC, MM, YW, TO, BC, AC, and LWJ declare no competing financial interests.